
## Michael Froehner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5298119/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Complications Following Radical Cystectomy for Bladder Cancer in the Elderly. European Urology, 2009, 56, 443-454.	1.9	242
2	Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. European Urology, 2015, 67, 460-467.	1.9	190
3	Comparison of the American Society of Anesthesiologists Physical Status classification with the Charlson score as predictors of survival after radical prostatectomy. Urology, 2003, 62, 698-701.	1.0	70
4	Direct comparison of multiparametric magnetic resonance imaging ( <scp>MRI</scp> ) results with final histopathology in patients with proven prostate cancer in <scp>MRI</scp> /ultrasonographyâ€ŧusion biopsy. BJU International, 2016, 118, 213-220.	2.5	68
5	Prospective comparison of transperineal magnetic resonance imaging/ultrasonography fusion biopsy and transrectal systematic biopsy in biopsyâ€naÃīve patients. BJU International, 2018, 121, 53-60.	2.5	47
6	Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients. European Urology Oncology, 2018, 1, 91-100.	5.4	46
7	Perioperative Complications after Radical Prostatectomy: Open versus Robot-Assisted Laparoscopic Approach. Urologia Internationalis, 2013, 90, 312-315.	1.3	42
8	Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer. Clinical Biochemistry, 2019, 64, 60-63.	1.9	36
9	Detailed Analysis of Charlson Comorbidity Score as Predictor of Mortality After Radical Prostatectomy. Urology, 2008, 72, 1252-1257.	1.0	34
10	Relationship of the Number of Removed Lymph Nodes to Bladder Cancer and Competing Mortality After Radical Cystectomy. European Urology, 2014, 66, 987-990.	1.9	34
11	Integrated prostate cancer centers might cause an overutilization of radiotherapy for low-risk prostate cancer: A comparison of treatment trends in the United States and Germany from 2004 to 2011. Radiotherapy and Oncology, 2015, 115, 90-95.	0.6	29
12	Prediction of cancerâ€specific survival after radical cystectomy in <scp>pT4a</scp> urothelial carcinoma of the bladder: development of a tool for clinical decisionâ€making. BJU International, 2016, 117, 272-279.	2.5	29
13	Urinary Tract-Related Quality of Life after Radical Prostatectomy: Open Retropubic versus Robot-Assisted Laparoscopic Approach. Urologia Internationalis, 2013, 90, 36-40.	1.3	28
14	Decreased Overall and Bladder Cancer–Specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis. European Urology, 2016, 69, 984-987.	1.9	27
15	Role of WNT5A receptors FZD5 and RYK in prostate cancer cells. Oncotarget, 2018, 9, 27293-27304.	1.8	27
16	Preoperative cardiopulmonary risk assessment as predictor of early noncancer and overall mortality after radical prostatectomy. Urology, 2003, 61, 596-600.	1.0	26
17	Feasibility and Limitations of Comorbidity Measurement in Patients Undergoing Radical Prostatectomy. European Urology, 2005, 47, 190-195.	1.9	26
18	Which patients are at the highest risk of dying from competing causes â‰ <b>‡</b> 0 years after radical prostatectomy?. BJU International, 2012, 110, 206-210.	2.5	24

MICHAEL FROEHNER

#	Article	IF	CITATIONS
19	Which Conditions Contributing to the Charlson Score Predict Survival After Radical Prostatectomy?. Journal of Urology, 2004, 171, 697-699.	0.4	23
20	Age, American Society of Anesthesiologists physical status classification and Charlson score are independent predictors of 90-day mortality after radical cystectomy. World Journal of Urology, 2016, 34, 1123-1129.	2.2	21
21	Molecular Therapy in Urologic Oncology. Urologia Internationalis, 2007, 79, 1-7.	1.3	20
22	A combined index to classify prognostic comorbidity in candidates for radical prostatectomy. BMC Urology, 2014, 14, 28.	1.4	20
23	Treatment of Bone Metastases in Urologic Malignancies. Urologia Internationalis, 2014, 93, 249-256.	1.3	18
24	Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node–Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score–Weighted Competing Risks Analysis. European Urology Focus, 2018, 4, 252-259.	3.1	18
25	Lack of efficacy of imatinib in a patient with metastatic Leydig cell tumor. Cancer Chemotherapy and Pharmacology, 2006, 58, 716-718.	2.3	17
26	Growth of a Level III Vena Cava Tumor Thrombus Within 1 Month. Urology, 2016, 90, e1-e2.	1.0	16
27	Interaction Between Age and Comorbidity as Predictors of Mortality After Radical Prostatectomy. Journal of Urology, 2008, 179, 1823-1829.	0.4	15
28	Validation of an Age-adjusted Prostate Cancer–Specific Comorbidity Index. European Urology, 2016, 69, 764-766.	1.9	15
29	PSMA-PET/CT-Positive Paget Disease in a Patient with Newly Diagnosed Prostate Cancer: Imaging and Bone Biopsy Findings. Case Reports in Urology, 2017, 2017, 1-3.	0.3	15
30	Urinary MicroRNAs as Potential Markers for Non-Invasive Diagnosis of Bladder Cancer. International Journal of Molecular Sciences, 2020, 21, 3814.	4.1	15
31	ProstaTrend—A Multivariable Prognostic RNA Expression Score for Aggressive Prostate Cancer. European Urology, 2020, 78, 452-459.	1.9	15
32	Comorbidity is poor predictor of survival in patients undergoing radical prostatectomy after 70 years of age. Urology, 2006, 68, 583-586.	1.0	14
33	Comparison of the Clinical Value of Complexed PSA and Total PSA in the Discrimination between Benign Prostatic Hyperplasia and Prostate Cancer. Urologia Internationalis, 2006, 76, 27-30.	1.3	14
34	Which comorbidity classification best fits elderly candidates for radical prostatectomy?. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 461-467.	1.6	14
35	Urinary transcript quantitation of CK20 and IGF2 for the non-invasive bladder cancer detection. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1757-1769.	2.5	14
36	Predicting Competing Mortality in Patients Undergoing Radical Prostatectomy Aged 70 yr or Older. European Urology, 2017, 71, 710-713.	1.9	12

MICHAEL FROEHNER

#	Article	IF	CITATIONS
37	Evaluation of Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy in Patients with Low-Risk Prostate Cancer Under Active Surveillance Undergoing Surveillance Biopsy. Urologia Internationalis, 2018, 100, 155-163.	1.3	12
38	Predicting 90-day and long-term mortality in octogenarians undergoing radical cystectomy. BMC Urology, 2018, 18, 91.	1.4	12
39	Validation of the Preoperative Score to Predict Postoperative Mortality in Patients Undergoing Radical Cystectomy. European Urology Focus, 2019, 5, 197-200.	3.1	12
40	Adult prostate sarcoma diagnosed from tissue spontaneously excreted through the urethra. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 119-120.	1.6	11
41	Derivatives of prostateâ€specific antigen as predictors of incidental prostate cancer. BJU International, 2009, 104, 25-28.	2.5	11
42	Nomogram Underestimates 10-year Survival in Healthy Men Selected for Radical Prostatectomy at Age 70 Years or Older. Urology, 2009, 73, 610-613.	1.0	11
43	Adult inguinoscrotal sarcomas: outcome analysis of 21 cases, systematic review of the literature and meta-analysis. World Journal of Urology, 2014, 32, 445-451.	2.2	11
44	Prostate-specific Membrane Antigen-targeted Ligand Positron Emission Tomography/Computed Tomography and Immunohistochemical Findings in a Patient With Synchronous Metastatic Penile and Prostate Cancer. Urology, 2017, 101, e5-e6.	1.0	11
45	Leiomyosarcoma of the Urinary Bladder in Adult Patients: A Systematic Review of the Literature and Meta-Analysis. Urologia Internationalis, 2019, 102, 96-101.	1.3	11
46	[68Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study. EJNMMI Research, 2020, 10, 135.	2.5	11
47	Gastrointestinal stromal tumor presenting as a scrotal mass. International Journal of Urology, 2004, 11, 445-447.	1.0	10
48	Second Cancers as Competing Causes of Death After Radical Prostatectomy. Journal of Urology, 2009, 182, 967-971.	0.4	10
49	Survival analysis in men undergoing radical prostatectomy at an age of 70 years or older. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 628-634.	1.6	10
50	Urinary immunocytology for primary bladder B cell lymphoma. Urology, 2004, 63, 381-383.	1.0	9
51	Surgical resection of locally recurrent renal cell carcinoma after nephrectomy: Oncological outcome and predictors of survival. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 11.e1-11.e6.	1.6	9
52	68Ga-RM2 PET in PSMA- positive and -negative prostate cancer patients. Nuklearmedizin - NuclearMedicine, 2019, 58, 352-362.	0.7	9
53	Successful Chemotherapy for Advanced Nonseminomatous Germ-Cell Tumor in a Patient Undergoing Chronic Hemodialysis. Journal of Clinical Oncology, 2007, 25, 1282-1284.	1.6	8
54	Adult urologic sarcoma: Experience during 2 decades. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 985-989.	1.6	8

#	Article	IF	CITATIONS
55	Does increasing life expectancy affect competing mortality after radical prostatectomy?. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 413-418.	1.6	8
56	Splenunculus Masquerading as Prostate-specific Membrane Antigen-positive Lymph Node Metastasis in a Patient With Prostate-specific Antigen Relapse After Radical Prostatectomy. Urology, 2016, 94, e1-e2.	1.0	8
57	Testicular cancer patients undergoing cisplatin based chemotherapy exhibit temporary olfactory threshold scores changes. European Archives of Oto-Rhino-Laryngology, 2017, 274, 2813-2818.	1.6	8
58	Competing Mortality Contributes to Excess Mortality in Patients with Poor-Risk Lymph Node-Positive Prostate Cancer Treated with Radical Prostatectomy. Urologia Internationalis, 2012, 89, 148-154.	1.3	7
59	Comparison of tumor- and comorbidity-related predictors of mortality after radical prostatectomy. Scandinavian Journal of Urology and Nephrology, 2005, 39, 449-454.	1.4	6
60	Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer, 2011, 117, 2577-2577.	4.1	6
61	Evaluation of Transperineal Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy Compared to Transrectal Systematic Biopsy in the Prediction of Tumour Aggressiveness in Patients with Previously Negative Biopsy. Urologia Internationalis, 2019, 102, 20-26.	1.3	6
62	Long-Term Mortality in Patients with Positive Lymph Nodes at the Time of Radical Prostatectomy. Urologia Internationalis, 2019, 103, 427-432.	1.3	6
63	Only <10% of Patients Selected for Radical Prostatectomy Reach the Competing Mortality Rate of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). European Urology Focus, 2019, 5, 361-364.	3.1	6
64	11C-Acetate positron emission tomography for occult prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 410-411.	1.6	5
65	Magnetic resonance imaging of bone metastases in patients with nonseminomatous germ cell tumors. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 201-206.	1.6	5
66	Androgen Deprivation Therapy and Alzheimer's Disease. Journal of Clinical Oncology, 2016, 34, 2801-2801.	1.6	5
67	Level of education and mortality after radical prostatectomy. Asian Journal of Andrology, 2017, 19, 173.	1.6	5
68	Prostate-specific Antigen-negative Prostate Cancer Recurrence?. Urology, 2013, 81, e17-e18.	1.0	4
69	Renal Sarcoidosis Mimicking Xanthogranulomatous Pyelonephritis. Urology, 2016, 97, e19-e20.	1.0	4
70	Changing comorbidity classification patterns at radical prostatectomy during a 10-year period. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 26-31.	1.6	3
71	In Regard to Nanda et al. International Journal of Radiation Oncology Biology Physics, 2013, 87, 431.	0.8	3
72	Locally Advanced Prostate Cancer: Optimal Therapy in Older Patients. Drugs and Aging, 2013, 30, 959-967.	2.7	3

#	Article	IF	CITATIONS
73	Re: Atiqullah Aziz, Matthias May, Maximilian Burger, et al. PROMETRICS 2011 research group. Prediction of 90-day Mortality After Radical Cystectomy for Bladder Cancer in a Prospective European Multicenter Cohort. Eur Urol 2014;66:156–163. European Urology, 2014, 66, e13.	1.9	3
74	Testing of a Novel Easy-to-use Mortality Index in a Radical Prostatectomy Cohort. Urology, 2014, 84, 307-313.	1.0	3
75	Reply. Urology, 2014, 84, 312-313.	1.0	2
76	Re: Zhu etÂal.: The Expression and Evaluation of Androgen Receptor in Human Renal Cell Carcinoma (Urology 2014;83:510.e19-24). Urology, 2014, 84, 734-735.	1.0	2
77	Re: Jim C. Hu, Giorgio Gandaglia, Pierre I. Karakiewicz, et al. Comparative Effectiveness of Robot-assisted Versus Open Radical Prostatectomy Cancer Control. Eur Urol 2014;66:666–72. European Urology, 2014, 66, e85.	1.9	2
78	Re: Syed Johar Raza, Timothy Wilson, James O. Peabody, et al. Long-term Oncologic Outcomes Following Robot-assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. Eur Urol 2015;68:721–8. European Urology, 2015, 68, e109.	1.9	2
79	Re: Malte Rieken, Shahrokh F. Shariat, Luis A. Kluth, et al. Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.05.038. European Urology, 2015. 68. e103.	1.9	2
80	Selection Effects May Explain Smoking-related Outcome Differences After Radical Cystectomy. European Urology Focus, 2018, 4, 395-398.	3.1	2
81	Comorbidity and survival of patients selected for radical prostatectomy at an age of 75 years or older. Asian Journal of Andrology, 2013, 15, 667-671.	1.6	2
82	The Management of Localized or Locally Advanced Prostate Cancer. American Journal of Cancer, 2002, 1, 387-396.	0.4	1
83	Malignant fibrous histiocytoma masquerading as germ cell tumor by producing beta-human chorionic gonadotropin and neuron-specific enolase. Urology, 2003, 62, 551.	1.0	1
84	Response to "Predictors of Prostate Cancer–Specific Mortality in Elderly Men With Intermediate-Risk Prostate Cancer Treated With Brachytherapy With or Without External Beam Radiation Therapy―(Int J) Tj ETQo 2010, 76, 1274.	0 0 0 rgB	T /Qverlock 1
85	Re: Association of Androgen Deprivation Therapy with Cardiovascular Death in Patients with Prostate Cancer: A Meta-Analysis of Randomized Trials. European Urology, 2012, 62, 350.	1.9	1
86	Approaches to radical prostatectomy. Journal of Comparative Effectiveness Research, 2014, 3, 451-453.	1.4	1
87	Charlson score and competing mortality. Cancer, 2014, 120, 4003-4003.	4.1	1
88	Re: Karim A. Touijer, Clarisse R. Mazzola, Daniel D. Sjoberg, Peter T. Scardino, James A. Eastham. Long-term Outcomes of Patients with Lymph Node Metastasis Treated with Radical Prostatectomy Without Adjuvant Androgen-deprivation Therapy. Eur Urol 2014;65:20–5. European Urology, 2014, 65, e24.	1.9	1
89	Should the Urologist Treat Castration Resistant Prostate Cancer?. Journal of Urology, 2015, 194, 286-286.	0.4	1
90	Re: Firas Abdollah, Giorgio Gandaglia, Nazareno Suardi, et al. More Extensive Pelvic Lymph Node Dissection Improves Survival in Patients with Node-positive Prostate Cancer. Eur Urol 2015;67:212–9. European Urology, 2015, 67, e112.	1.9	1

#	Article	IF	CITATIONS
91	Re: Grace L. Lu-Yao, Peter C. Albertsen, Dirk F. Moore, Yong Lin, Robert S. DiPaola, Siu-Long Yao. Fifteen-year Outcomes Following Conservative Management Among Men aged 65 Years or Older with Localized Prostate Cancer. Eur Urol 2015;68:805–11. European Urology, 2016, 69, e130.	1.9	1
92	Renal staghorn calculus?. Urology, 2005, 65, 171.	1.0	0
93	Re: Robot-Assisted versus Open Radical Prostatectomy: The Differential Effect of Regionalization, Procedure Volume and Operative Approach. Journal of Urology, 2013, 190, 1440-1441.	0.4	0
94	Socio-economic deprivation and cancer survival in Germany. International Journal of Cancer, 2014, 135, 1989-1989.	5.1	0
95	Re: Kenneth G. Nepple, Andrew J. Stephenson, Dorina Kallogjeri, et al. Mortality After Prostate Cancer Treatment with Radical Prostatectomy, External-Beam Radiation Therapy, or Brachytherapy in Men Without Comorbidity. Eur Urol 2013;64:372–8. European Urology, 2014, 65, e41.	1.9	0
96	Predictive Significance of Confirmation Biopsies in Patients on Active Surveillance. European Urology, 2014, 66, 414-415.	1.9	0
97	Prostate-specific Antigen Pox Virus Vaccination for Recurrent Prostate Cancer. European Urology, 2015, 68, 372-373.	1.9	0
98	Simultaneous Targeting of the Akt and Androgen Receptor Pathways. European Urology, 2015, 67, 991-992.	1.9	0
99	Re: Jesse D. Sammon, Firas Abdollah, Anthony D'Amico, et al. Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. Eur Urol 2015;68:756–65 European Urology, 2016, 69, e128.	1.9	0
100	Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:21–30. European Urology, 2016, 70, e9.	1.9	0
101	Delayed Radiographic Manifestation of Renal Pseudoaneurysms After Blunt Trauma. Urology, 2017, 103, e9-e10.	1.0	0
102	Age and Charlson Score. Annals of Surgical Oncology, 2017, 24, 677-678.	1.5	0
103	Chronically Infected Urachal Remnant Mimicking Tumor With Peritoneal Carcinomatosis. Urology, 2018, 116, e3-e4.	1.0	0
104	Re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. Eur Urol 2019;75:552–5. European Urology, 2019, 76, e75.	1.9	0
105	Screening and efficacy of radical prostatectomy. Asian Journal of Andrology, 2013, 15, 441-442.	1.6	ο